Laser diffractometry as a technique for the rapid assessment of aerosol particle size from inhalers

被引:84
作者
Mitchell, Jolyon P.
Nagel, Mark W.
Nichols, Steve
Nerbrink, Ola
机构
[1] Trudell Med Int, London, ON N5V 5G4, Canada
[2] Novo Nordisk AS, Hillerod, Denmark
来源
JOURNAL OF AEROSOL MEDICINE-DEPOSITION CLEARANCE AND EFFECTS IN THE LUNG | 2006年 / 19卷 / 04期
关键词
laser diffraction; particle size analysis; inhaler testing;
D O I
10.1089/jam.2006.19.409
中图分类号
R1 [预防医学、卫生学];
学科分类号
1004 ; 120402 ;
摘要
The rapid assessment of aerosols produced by medicinal inhalers is highly desirable from several standpoints, including the assurance of product quality, the development of new delivery systems, and the need to meet an increasing requirement by regulatory bodies for reliable in vitro performance data. Particle size analysis has traditionally been undertaken by cascade impactor on account of the direct assessment of active pharmaceutical ingredient(s) (APIs) that is possible by this method. However, laser diffractometry is less labor-intensive, more rapid, and can be a less invasive procedure. The technique provides meaningful results; as long as precautions are taken to validate that the measurements are an accurate reflection of the distribution of API mass as a function of particle or droplet size. We begin the review by examining the underlying theory of the laser diffraction method. After a brief description of current laser diffractometers used in inhaler measurements, we continue by examining the range of applications by inhaler class. We then examine the basis upon which inhaler measurements made by laser-diffractometry can be compared with equivalent particle size distribution data from compendial techniques. We conclude the assessment of the technique by developing guidelines for its valid application as a component of the range of in vitro methods that are available for inhaler performance assessment.
引用
收藏
页码:409 / 433
页数:25
相关论文
共 89 条
  • [51] Mitchell J. P., 2000, KONA, V18, P41, DOI DOI 10.14356/K0NA.2000010
  • [52] Mitchell Jolyon P, 2003, Respir Care, V48, P46
  • [53] Time-of-flight aerodynamic particle size analyzers: Their use and limitations for the evaluation of medical aerosols
    Mitchell, JP
    Nagel, MW
    [J]. JOURNAL OF AEROSOL MEDICINE-DEPOSITION CLEARANCE AND EFFECTS IN THE LUNG, 1999, 12 (04): : 217 - 240
  • [54] Cascade impactors for the size characterization of aerosols from medical inhalers: Their uses and limitations
    Mitchell, JP
    Nagel, MW
    [J]. JOURNAL OF AEROSOL MEDICINE-DEPOSITION CLEARANCE AND EFFECTS IN THE LUNG, 2003, 16 (04): : 341 - +
  • [55] Size analysis of a pressurized metered dose inhaler-delivered suspension formulation by the API aerosizer time-of-flight aerodynamic particle size analyzer
    Mitchell, JP
    Nagel, MW
    Archer, AD
    [J]. JOURNAL OF AEROSOL MEDICINE-DEPOSITION CLEARANCE AND EFFECTS IN THE LUNG, 1999, 12 (04): : 255 - 264
  • [56] MOSLEMI P, 2002, RESP DRUG DEL, V8, P619
  • [57] Mühlenweg H, 1999, PART PART SYST CHAR, V16, P47, DOI 10.1002/(SICI)1521-4117(199906)16:2<47::AID-PPSC47>3.0.CO
  • [58] 2-9
  • [59] WHY DO MEDICAL NEBULIZERS DIFFER IN THEIR OUTPUT AND PARTICLE-SIZE CHARACTERISTICS
    NERBRINK, O
    DAHLBACK, M
    HANSSON, HC
    [J]. JOURNAL OF AEROSOL MEDICINE-DEPOSITION CLEARANCE AND EFFECTS IN THE LUNG, 1994, 7 (03): : 259 - 276
  • [60] Validation of laser diffraction method as a substitute for cascade impaction in the European project for a nebulizer standard
    None, LV
    Grimbert, D
    Becquemin, MH
    Boissinot, E
    Le Pape, A
    Lemarié, E
    Diot, P
    [J]. JOURNAL OF AEROSOL MEDICINE-DEPOSITION CLEARANCE AND EFFECTS IN THE LUNG, 2001, 14 (01): : 107 - 114